<?xml version="1.0" encoding="UTF-8"?>
<p id="Par41">However, many significant challenges remain. Current vaccines are largely limited to offering homosubtypic immunity, depend on accurate forecasting of anticipated seasonal strains and offer little protection against emergent pandemic viruses. More effective vaccines that provide heterosubtypic (universal) and long-lasting protection are needed; great strides have been made in these directions, but such vaccines remain elusive. The advent of antimicrobial drugs has greatly alleviated influenza mortality, but rising rates of resistance against frontline antibiotics challenge our ability to combat severe disease, particularly bacterial co-infections.</p>
